Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

SNIPR Biome

Main focus: Treatment of bacterial infections

Company stage: Pre-clinical

Diseases: Bloodstream infections caused by E. coli, other infections

Genome editing tool: CRISPR-Cas

Funding stage: Private

Location: Copenhagen, Denmark

Website: https://www.sniprbiome.com/

Partners: Novo Nordisk

SNIPR Biome is a Danish, pre-clinical stage company. The company is focused on novel CRISPR-based antibacterial therapies. The company has patents on several CRISPR-Cas technologies including the Cas9, Cas3 and Cas12a enzymes. While SNIPR Biome has not revealed an official pipeline, it has disclosed the use of its DNA-based CRISPR-guided vector platform to generate next-generation antibiotic therapies.

Your Latest CMN News

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Company: SNIPR Biome

Search CRISPR Medicine